Absolute Quantitation of SARS-CoV-2 using the Combinati Absolute Q Digital PCR Platform and Triplex Assay
Christina Bouwens & Adam Langston
Thursday, August 27th 10am PST
The Absolute Q Digital PCR platform paired with the |Q| SARS-CoV-2 Triplex Assay provides unmatched sensitivity for rare targets and a streamlined multiplex assay using a single instrument with an easy workflow. The technology and platform are versatile and can be adapted to a wide range of nucleic acid detection applications requiring absolute quantification. The Absolute Q simplifies dPCR with best-in-class data consistency, short sample-to-answer time, and flexible multi-color multiplexing capabilities. These features will increase accessibility of dPCR as a tool to enable accelerated responses to global public health emergencies such as the COVID-19 pandemic.
Christina Bouwens is a Senior Application Scientist at Combinati. She has a background in digital PCR assay development and next generation sequencing technologies with specific focus on applications to cancer biology and precision medicine. She was the recipient of the 2018 AMP Technologist Award, and has contributed to 11 peer-reviewed publications in the Oncology space – including 2 first authorship’s utilizing digital PCR technology for personalized circulating tumor DNA detection and monitoring.
Adam Langston is the Vice President of Sales and Business Development at Combinati. With a decade of experience in life science equipment and reagent commercialization, he understands researchers’ needs both in terms of how and why scientists evaluate and acquire new technologies. Adam considers himself a customer advocate above all else, and is excited to share and support Combinati’s innovative solutions with investigators all over the world.